Format

Send to

Choose Destination
J Labelled Comp Radiopharm. 2019 Aug;62(10):656-672. doi: 10.1002/jlcr.3750.

Exendin-4 analogs in insulinoma theranostics.

Author information

1
Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.
2
Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland.
3
Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium.

Abstract

in English, Dutch

Insulinomas, neuroendocrine tumors arising from pancreatic beta cells, often show overexpression of the glucagon-like peptide-1 receptor. Therefore, imaging with glucagon-like peptide analog exendin-4 can be used for diagnosis and preoperative localization. This review presents an overview of the development and clinical implementation of exendin-based tracers for nuclear imaging, and the potential use of exendin-4 based tracers for optical imaging and therapeutic applications such as peptide receptor radionuclide therapy or targeted photodynamic therapy.

KEYWORDS:

GLP-1 receptor; exendin-4; insulinoma; peptide receptor radionuclide therapy (PRRT); positron emission tomography (PET); single-photon emission computed tomography (SPECT); targeted photodynamic therapy (tPDT); theranostics

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center